OncoMatch

OncoMatch/Clinical Trials/NCT06408116

Predicting Esophageal Cancer Borders Using PET-Imaging

Is NCT06408116 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chemotherapy for esophagus cancer, stage i.

Phase 2RecruitingUniversity Hospital HeidelbergNCT06408116Data as of Jun 2026Location: Germany

Treatment: ChemotherapyThe study examines the diagnostic precision of endosonography, mpMRI and PET/CT in defining tumor boundaries and tumor spread before and after neoadjuvant therapy and definitive surgery.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Chemotherapy

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage I, II

Prior therapy

Cannot have received: radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06408116 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior radiation therapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage I or II is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify